Diagnostic Dominance | Hologic's molecular diagnostics segment shows robust 8% growth, highlighting the company's strength in advanced medical technologies and potential for market expansion |
Breast Health Hurdles | Explore Hologic's challenges in its traditionally strong breast health sector and the potential impact on overall company performance and market position |
Strategic Capital Use | Delve into Hologic's focus on M&A and share buybacks, balancing short-term EPS support with long-term growth investments in a competitive medical technology landscape |
Future Outlook | Analysts project price targets ranging from $70 to $89, reflecting mixed views on Hologic's growth prospects amid ongoing tariff challenges and the need for Q4 FY'25 rebound |
Metrics to compare | HOLX | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipHOLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.9x | 19.1x | −0.4x | |
PEG Ratio | −1.31 | −0.26 | 0.00 | |
Price/Book | 3.2x | 1.8x | 2.6x | |
Price / LTM Sales | 4.1x | 2.7x | 3.0x | |
Upside (Analyst Target) | 0.0% | 66.7% | 50.7% | |
Fair Value Upside | Unlock | 22.2% | 6.5% | Unlock |